Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PROTACs: The Future of Leukemia Therapeutics.
Anwar Z, Ali MS, Galvano A, Perez A, La Mantia M, Bukhari I, Swiatczak B. Anwar Z, et al. Among authors: galvano a. Front Cell Dev Biol. 2022 Sep 2;10:851087. doi: 10.3389/fcell.2022.851087. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36120561 Free PMC article. Review.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
Dietary restriction: could it be considered as speed bump on tumor progression road?
Cangemi A, Fanale D, Rinaldi G, Bazan V, Galvano A, Perez A, Barraco N, Massihnia D, Castiglia M, Vieni S, Bronte G, Mirisola M, Russo A. Cangemi A, et al. Among authors: galvano a. Tumour Biol. 2016 Jun;37(6):7109-18. doi: 10.1007/s13277-016-5044-8. Epub 2016 Apr 4. Tumour Biol. 2016. PMID: 27043958 Review.
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.
Massihnia D, Galvano A, Fanale D, Perez A, Castiglia M, Incorvaia L, Listì A, Rizzo S, Cicero G, Bazan V, Castorina S, Russo A. Massihnia D, et al. Among authors: galvano a. Oncotarget. 2016 Sep 13;7(37):60712-60722. doi: 10.18632/oncotarget.10858. Oncotarget. 2016. PMID: 27474173 Free PMC article. Review.
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients.
Passiglia F, Galvano A, Castiglia M, Incorvaia L, Calò V, Listì A, Mazzarisi S, Perez A, Gallina G, Rizzo S, Soto Parra H, Bazan V, Russo A. Passiglia F, et al. Among authors: galvano a. Ther Adv Med Oncol. 2019 Apr 16;11:1758835919839928. doi: 10.1177/1758835919839928. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31019571 Free PMC article.
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials.
Galvano A, Gristina V, Malapelle U, Pisapia P, Pepe F, Barraco N, Castiglia M, Perez A, Rolfo C, Troncone G, Russo A, Bazan V. Galvano A, et al. ESMO Open. 2021 Jun;6(3):100124. doi: 10.1016/j.esmoop.2021.100124. Epub 2021 Apr 30. ESMO Open. 2021. PMID: 33940346 Free PMC article. Review.
98 results